In the third pathway, anti-CD47 antibody could eliminate breast cancer cells via traditional Fc-dependent mechanisms, including neutrophil-mediated antibody-dependent cellular cytotoxicity (ADCC) and macrophage-mediated antibody-dependent cellular phagocytosis (ADCP) (12, 61). Here, CD47 is linked to breast carcinoma.